4-(pyridin-2-yl)piperidine-4-carbonitrile dihydrochloride | 167263-05-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(pyridin-2-yl)piperidine-4-carbonitrile dihydrochloride
• 英文别名: 4-(Pyridin-2-yl)piperidine-4-carbonitrile hydrochloride；4-pyridin-2-ylpiperidine-4-carbonitrile;hydrochloride
• CAS: 167263-05-0
• 化学式: C₁₁H₁₃N₃*2ClH
• mdl: MFCD25973099
• 分子量: 260.166
• InChiKey: SMDVDDISQIOLCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  48.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(pyridin-2-yl)piperidine-4-carbonitrile dihydrochloride 在 氢氧化钾 作用下， 生成 4-(pyridin-2-yl)-piperidine-4-carboxylic acid hydrochloride
  参考文献：
  名称：

  Substituted pyrrolidin-3-yl-alkyl-piperidines

  摘要：

  本发明涉及取代吡咯烷基哌啶基的化合物及其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途，如快速激肽拮抗作用，特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。

  公开号：

  US05824690A1
• 作为产物：
  描述：

  2-吡啶乙腈 在 盐酸 、 sodium hydride 作用下， 生成 4-(pyridin-2-yl)piperidine-4-carbonitrile dihydrochloride
  参考文献：
  名称：

  Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones

  摘要：

  A series of alpha(1a) receptor antagonists derived from a 4-aryl-3,4-dihydropyridine-2-one heterocycle is disclosed. Potency in the low nanomolar to picomolar range along with high selectivity was obtained. In vivo efficacy in a prostate contraction model in rats was observed with a few derivatives. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00696-4

文献信息

• [EN] AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 À BASE D'AMINOBENZOQUINAZOLINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011084371A1

  公开（公告）日：2011-07-14

  The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的氨基苯并喹唑醌酮化合物，其为M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍等方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物。
• Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US10548899B2

  公开（公告）日：2020-02-04

  The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

  本发明提供了一种具有胆碱能肌动蛋白M1受体阳性变构调节剂活性的化合物，可能作为药物使用，例如作为预防或治疗阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、Lewy体痴呆等的药剂。本发明涉及一种由式（I）表示的化合物或其盐。在式（I）中，每个符号如所附说明书中所述。
• [EN] N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 CONTENANT DES LACTAMES LIÉS À N
  申请人：MERCK SHARP & DOHME

  公开号：WO2012158475A1

  公开（公告）日：2012-11-22

  The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一般式（I）的N-连接内酰胺化合物，这些化合物是M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包括这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• PIPERIDINE COMPOUND AND PEST-CONTROL USE THEREFORE
  申请人：Sumitomo Chemical Company Limited

  公开号：EP2845851A1

  公开（公告）日：2015-03-11

  A piperidine compound represented by the following Formula (1): wherein ring A, ring B, and ring C are the same or differen t and each represent a benzene ring or a nitrogen-containing heteroaromatic ring; W represents a C1-C4 alkylene or alkenylene group; X, Y, and Z are the same o r different and each represent a halogen atom, a C1-C6 alkyl group, a halo C1-C6 alkyl group, a C1-C6 alkoxy group, or a halo C1-C6 alkoxy group; m, n, and p are the same or different and each represent an integer of 0 to 5; when m is greater than or equal two 2, the Xs are t he same or different; when n is greater than or equal to 2, the Ys are the same or different; and when p is greater th an or equal to 2, the Zs are the same or different has an excellent controlling efficacy against pests.

  由以下式（1）表示的一种哌啶化合物：其中环A、环B和环C相同或不同，每个代表苯环或含氮杂环；W代表C1-C4烷基或烯基基团；X、Y和Z相同或不同，每个代表卤素原子、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基或卤代C1-C6烷氧基；m、n和p相同或不同，每个代表0到5的整数；当m大于或等于2时，X相同或不同；当n大于或等于2时，Y相同或不同；当p大于或等于2时，Z相同或不同，对害虫具有出色的控制效果。
• Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators
  申请人：Kuduk Scott D.

  公开号：US20120264761A1

  公开（公告）日：2012-10-18

  The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的氨基苯并喹唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的方法。